Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences

Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP - News), announced that senior management will present a corporate overview and clinical pipeline updates at two upcoming healthcare investor conferences:

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

-- The 7th Annual BIO Investor Forum, to be held October 29-31, 2008 at the Palace Hotel in San Francisco, CA. Raptor's presentation will take place on Wednesday, October 29 at 4:45pm ET (1:45pm PT) in Telegraph Hill. A live audio webcast of the presentation will be http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=RAPTOR&item_id=1996013

-- The Rodman & Renshaw 10th Annual Healthcare Conference, to be held November 10-12, 2008 at New York Palace Hotel in New York, NY. Raptor's presentation will take place on Tuesday, November 11 at 9:30am ET (6:30am PT) in Holmes II (4th floor). A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/rrshq14/rptp.ob

Both webcasts will be archived for 30 days and accessible through the investor relations section of Raptor's website at www.raptorpharma.com.

For more information on BIO Investor Forum conference please visit: http://investorforum.bio.org/opencms/bif/2008/

For more information on Rodman & Renshaw's 10th Annual Healthcare Conference please visit: http://www.rodmanandrenshaw.com/conferences

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is a publicly traded biotechnology company dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it may have the greatest impact. Raptor is involved in clinical development of its proprietary Delayed-Release Cysteamine ("DR Cysteamine") product candidate in nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease and Batten Disease, and its ConviviaTM product candidate in aldehyde dehydrogenase ("ALDH2") deficiency. In its preclinical programs Raptor bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins which are designed to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTideTM, WntTideTM and NeuroTransTM.

For additional information, please visit www.raptorpharma.com.